Poly (ADP-ribose) polymerase (PARP) inhibitors represent a significant advance in the treatment of ovarian cancer. This new class of drugs, which includes olaparib, targets the DNA repair pathways of cancer cells, specifically those with BRCA mutations, which are common in ovarian cancer. A key step forward was the SOLO (Study of Olaparib in Ovarian cancer) […]